Inovio set for first Zika vaccine human trial


The worldwide Zika vaccine race has reached a new milestone as Plymouth Meeting, PA’s Inovio Pharmaceuticals ($INO) says it has received the first approval to begin human testing on its candidate, GLS-5700.

With the FDA's green light, Inovio takes a step ahead of vaccine developers including those at the National Institutes of Health and India’s Bharat Biotech, both of which have been said to be in leading positions in the race, as well as Big Pharma vax player Sanofi ($SNY). Inovio’s Phase I study will test GLS-5700 in 40 healthy subjects using the biotech's DNA delivery system Cellectra.

Inovio says its candidate, developed in conjunction with South Korea’s GeneOne and academics in the U.S. and Canada, has succeeded in large and small animal models to this point. The team will now seek to apply the progress to humans, starting with dosing in the coming weeks. Interim Phase I results are anticipated yet this year, Inovio CEO J. Joseph Kim said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Kim, speaking with Bloomberg Video, said however that a vaccine could take years to reach the market. The company has been designing its vaccine since late last year and progressed to human trials "within 6 months," he added.

So far, the current Zika outbreak has spread to 58 countries and territories worldwide, resulting in scores of babies with microcephaly and sparking a global scramble for an effective vaccine.

Sanofi, seeking to apply its decades of experience in the flavivirus dengue, has said it’s working on Zika, while other leading vaccine makers--GlaxoSmithKline ($GSK), Merck ($MRK), Johnson & Johnson ($JNJ) and Pfizer ($PFE)--have all said they’re weighing their options. Reports last month said that some pharma are taking a cautious approach to the outbreak as they seek assurance that a potential vaccine could recoup research costs.

The NIH has said it’s hoping to start a human trial on its candidate yet this year, while Sanofi has previously said it could start clinical studies next year if all goes well.

- here’s the release
- more from Bloomberg Video

Related Articles:
Big Pharmas cautious on Zika vaccine development
Sanofi digs into details on hastened Zika effort


Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.